SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): December 10, 2010
(December 7, 2010)
CHINA
YONGXIN PHARMACEUTICALS INC.
(Exact name of registrant
as specified in Charter)
Delaware
|
000-26293
|
20-1661391
|
||
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File No.)
|
(IRS
Employee Identification No.)
|
927
Canada Court
City
of Industry, California 91748
(Address
of Principal Executive Offices)
(626)
581-9098
(Issuer
Telephone number)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers.
|
On
December 7, 2010, Mr. Harry Zhang resigned as the Chief Financial Officer of
China Yongxin Pharmaceuticals Inc. (the “Company”).
There
were no disagreements between Mr. Zhang and any officer or director of the
company. The Company provided a copy of the disclosures it is making
in response to this Item 5.02 to Mr. Zhang and informed him that he may furnish
the company as promptly as possible with a letter stating whether he agrees or
disagrees with the disclosures made in response to this Item 5.02, and that if
he disagrees, then the Company requests that he provide the respects in which he
does not agree with the disclosures. The Company will undertake to
file any letter received from Mr. Zhang, if any, as an exhibit to an amendment
to this Current Report on Form 8-K (“Form 8-K”) within two business days after
receipt.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
CHINA YONGXIN PHARMACEUTICALS INC. | |||
|
By:
|
/s/ Yongxin Liu | |
Yongxin Liu | |||
Chief
Executive Officer
|
|||
Dated: December
10, 2010